STRUCTURAL BIOLOGY SHARED RESOURCE The Structural Biology Shared Resource (STRBIO) provides a comprehensive platform of expertise, education, and infrastructure that enables LCCC researchers to perform cutting-edge structural biological studies. LCCC members have all the resources needed to determine macromolecular structures using X-ray crystallography, biomolecular NMR, and single-particle cryo-electron microscopy (cryoEM). This mission is accomplished through seven complementary components: 1) macromolecular X-ray crystallography, 2) multi-dimensional nuclear magnetic resonance (NMR) spectroscopy, 3) cryo-electron microscopy, 4) structural bioinformatics, 5) protein expression and purification, 6) synthesis of peptides and peptidomimetics, and 7) biophysical measurements of macromolecular properties in solution and their interactions. Each component of STRBIO is managed by an on-site director with a Ph.D. and years of relevant scientific and managerial experience. All core directors hold ranks of Assistant Research Professor or higher and most teach graduate-level classes in their respective disciplines. John Sondek (MT) continues as faculty director of STRBIO and leads this team of experienced directors. Dr. Sondek has over 20 years of experience in structural biology and drug discovery and meets bimonthly with core directors as a group to coordinate efforts and develop strategic plans. The STRBIO was used by 131 users last year. LCCC members accounted for 34% of the use. There are no alternatives to STRBIO on campus or at nearby academic institutions. In fact, STRBIO attracts numerous users from outside the UNC system due to its competitive rates and extensive services. STRBIO requests $119,631 for this SR, approximately 6% of the total operating budget of $1.9M. To accomplish its mission STRBIO will continue to expand services into areas of high demand, areas that take advantage of the inherent synergies embodied among the STRBIO components, and areas predicted to provide major advances in cancer biology including new fragment-based drug discovery and expanding capacity to label proteins isotopically.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089830
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications